Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Aarogyam UK | OTHER |
| Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University | OTHER |
| Samta Ayurveda Prakoshtha, India | UNKNOWN |
| Padmanabhama Ayurveda Hospital and Research Centre |
Not provided
Not provided
Not provided
Not provided
Specifically identified Ayurvedic preparations is recommended by ministry of AYUSH as post-exposure prophylaxis to efficaciously prevent a negative person who has come into contact with COVID-19-positive. Traditionally, recommended Ayurvedic preparations have been used as antioxidants, antimicrobial and anti-inflammatory properties. Particularly, Guduchi Ghanvati has been recognised with its ability to control viral attachment, viral replication and induce immune response in pre clinical settings, and found to be one among the most important drugs in Ayurveda to fight against COVID-19.
However, known gap in guideline implementation and its impact on preventing active infection in exposed cases is unclear. Study aimed to increase the use of recommended AYUSH guidelines by having registered AYUSH physicians provide these medications, when indicated, in community based participants after known exposure to the SARS-CoV-2 coronavirus.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ayurveda Care Group | Experimental | Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask Samshamani vati or Giloy Ghanavati |
|
| Usual Care Group | Active Comparator | Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Guduchi Ghanvati | Other | 500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with active COVID-19 | PCR- proven COVID-19 | 14-days following exposure |
| Measure | Description | Time Frame |
|---|---|---|
| Time to symptoms onset | Days until start of symptoms of COVID-19 | 14-days |
| Disease Severity | Visual Analog Scale of rating overall symptom severity (0 = no symptoms; 10 = most severe) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Neha Sharma | Aarogyam UK | Study Chair |
| Skanthesh Lakshmanan | Niramaya clinic, India | Study Chair |
| Isha Goyal | NMP Medical Research Institute, India | Principal Investigator |
| Abijith Venu | Aarogyam UK | Study Chair |
| Sahil Singhal | NMP Medical Research Institute | Study Director |
| Abhimanyu Kumar | Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NMP Medical Research Institute | Jaipur | Rajasthan | India | |||
| Padmnabham Ayurveda Hospital & Research Center |
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
| Standard guidelines | Other | Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask |
|
| 14 days |
| Jaipur |
| Rajasthan |
| India |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |